CR20200361A - Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof - Google Patents
Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereofInfo
- Publication number
- CR20200361A CR20200361A CR20200361A CR20200361A CR20200361A CR 20200361 A CR20200361 A CR 20200361A CR 20200361 A CR20200361 A CR 20200361A CR 20200361 A CR20200361 A CR 20200361A CR 20200361 A CR20200361 A CR 20200361A
- Authority
- CR
- Costa Rica
- Prior art keywords
- biomarker
- patients
- expression
- therapy
- tumour infiltrating
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 210000004698 lymphocyte Anatomy 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 abstract 6
- 230000014509 gene expression Effects 0.000 abstract 3
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 abstract 2
- 238000011467 adoptive cell therapy Methods 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/65—MicroRNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
<p>La presente invención se relaciona con un biomarcador útil en terapia celular adoptiva. El</p> <p>biomarcador en cuestión es el CD150, también denominado SLAM o SLAMF1. Aquí demostramos que la expresión del CD150 en productos de infusión de linfocitos infiltrantes de tumor se correlaciona con la tasa de respuesta observada en esos pacientes. La expresión alta de CD150 se encuentra en pacientes que continúan teniendo una respuesta completa y la expresión baja en pacientes que no responden a la terapia. La invención se refiere al uso del biomarcador para predecir la tasa de respuesta o estratificar a los pacientes para el tratamiento. También cubre el aprovechamiento de este receptor en regímenes de terapia celular adoptiva en general, que incluye, entre otros, la sobreexpresión del receptor en poblaciones de células T o el aislamiento de células que expresan CD150 en un esfuerzo por aumentar la eficacia.</p> <p> </p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1801067.8A GB201801067D0 (en) | 2018-01-23 | 2018-01-23 | Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof |
| PCT/GB2019/050188 WO2019145711A1 (en) | 2018-01-23 | 2019-01-23 | Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200361A true CR20200361A (es) | 2021-01-13 |
Family
ID=61283558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200361A CR20200361A (es) | 2018-01-23 | 2019-01-23 | Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20210000872A1 (es) |
| EP (2) | EP4233883A3 (es) |
| JP (1) | JP2021511079A (es) |
| KR (1) | KR20200112915A (es) |
| CN (1) | CN111886335A (es) |
| AU (1) | AU2019213201A1 (es) |
| BR (1) | BR112020014998A2 (es) |
| CA (1) | CA3089294A1 (es) |
| CL (1) | CL2020001943A1 (es) |
| CO (1) | CO2020010266A2 (es) |
| CR (1) | CR20200361A (es) |
| EA (1) | EA202091753A1 (es) |
| EC (1) | ECSP20050981A (es) |
| ES (1) | ES2948969T3 (es) |
| GB (1) | GB201801067D0 (es) |
| IL (1) | IL276167A (es) |
| MA (1) | MA51705A (es) |
| MX (1) | MX2020007728A (es) |
| PE (1) | PE20210843A1 (es) |
| PH (1) | PH12020551110A1 (es) |
| SG (1) | SG11202006875VA (es) |
| WO (1) | WO2019145711A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| GB201910605D0 (en) * | 2019-07-24 | 2019-09-04 | Immetacyte Ltd | Tumour infltracting lymphocyte therapy amd uses thereo |
| IL294098A (en) | 2019-12-20 | 2022-08-01 | Instil Bio Uk Ltd | Devices and methods for isolating lymphocytes infiltrating tumors and their use |
| CA3205464A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
| EP4263807A2 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
| WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| US20220313806A1 (en) | 2021-03-25 | 2022-10-06 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| SG11201508585PA (en) * | 2013-04-18 | 2015-11-27 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| CA2943389C (en) * | 2014-03-20 | 2023-10-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor-infiltrating lymphocytes for adoptive cell therapy |
| WO2017179015A1 (en) * | 2016-04-15 | 2017-10-19 | Glaxosmithkline Intellectual Property Development Limited | Compositions for the treatment of cancer |
-
2018
- 2018-01-23 GB GBGB1801067.8A patent/GB201801067D0/en not_active Ceased
-
2019
- 2019-01-23 KR KR1020207024069A patent/KR20200112915A/ko not_active Application Discontinuation
- 2019-01-23 WO PCT/GB2019/050188 patent/WO2019145711A1/en unknown
- 2019-01-23 ES ES19702676T patent/ES2948969T3/es active Active
- 2019-01-23 CN CN201980020942.7A patent/CN111886335A/zh active Pending
- 2019-01-23 MX MX2020007728A patent/MX2020007728A/es unknown
- 2019-01-23 EP EP23177650.1A patent/EP4233883A3/en active Pending
- 2019-01-23 AU AU2019213201A patent/AU2019213201A1/en not_active Abandoned
- 2019-01-23 JP JP2020560612A patent/JP2021511079A/ja not_active Ceased
- 2019-01-23 MA MA051705A patent/MA51705A/fr unknown
- 2019-01-23 SG SG11202006875VA patent/SG11202006875VA/en unknown
- 2019-01-23 BR BR112020014998-5A patent/BR112020014998A2/pt unknown
- 2019-01-23 PE PE2020001006A patent/PE20210843A1/es unknown
- 2019-01-23 CA CA3089294A patent/CA3089294A1/en active Pending
- 2019-01-23 EP EP19702676.8A patent/EP3743511B1/en active Active
- 2019-01-23 CR CR20200361A patent/CR20200361A/es unknown
- 2019-01-23 EA EA202091753A patent/EA202091753A1/ru unknown
-
2020
- 2020-07-20 IL IL276167A patent/IL276167A/en unknown
- 2020-07-22 PH PH12020551110A patent/PH12020551110A1/en unknown
- 2020-07-22 US US16/935,612 patent/US20210000872A1/en not_active Abandoned
- 2020-07-23 CL CL2020001943A patent/CL2020001943A1/es unknown
- 2020-08-20 CO CONC2020/0010266A patent/CO2020010266A2/es unknown
- 2020-08-21 EC ECSENADI202050981A patent/ECSP20050981A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021511079A (ja) | 2021-05-06 |
| PH12020551110A1 (en) | 2021-07-05 |
| EP3743511B1 (en) | 2023-06-07 |
| US20210000872A1 (en) | 2021-01-07 |
| ES2948969T3 (es) | 2023-09-22 |
| AU2019213201A1 (en) | 2020-08-06 |
| IL276167A (en) | 2020-09-30 |
| CL2020001943A1 (es) | 2021-02-26 |
| GB201801067D0 (en) | 2018-03-07 |
| SG11202006875VA (en) | 2020-08-28 |
| CN111886335A (zh) | 2020-11-03 |
| CA3089294A1 (en) | 2019-08-01 |
| EP3743511C0 (en) | 2023-06-07 |
| PE20210843A1 (es) | 2021-05-10 |
| MX2020007728A (es) | 2020-10-05 |
| WO2019145711A1 (en) | 2019-08-01 |
| EP4233883A2 (en) | 2023-08-30 |
| EP3743511A1 (en) | 2020-12-02 |
| MA51705A (fr) | 2020-12-02 |
| KR20200112915A (ko) | 2020-10-05 |
| CO2020010266A2 (es) | 2020-10-30 |
| BR112020014998A2 (pt) | 2020-12-29 |
| ECSP20050981A (es) | 2021-01-29 |
| EA202091753A1 (ru) | 2020-09-23 |
| EP4233883A3 (en) | 2023-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551110A1 (en) | Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof | |
| CR20220027A (es) | Terapia con linfocitos de infiltración tumoral y sus usos | |
| EA036698B9 (ru) | Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif | |
| PH12017500268A1 (en) | Antibodies and chimeric antigen receptors specific for cd19 | |
| MX359551B (es) | Agentes de union diana contra b7-h1. | |
| BR112016023523A2 (pt) | produtos de células t modificados em gene de composição definida | |
| EP4306636A3 (en) | Monolayer of pbmcs or bone-marrow cells and uses thereof | |
| WO2012054792A3 (en) | Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells | |
| Lindqvist et al. | T regulatory cells in B‐cell malignancy–tumour support or kiss of death? | |
| NZ609594A (en) | Eph receptor expression in tumor stem cells | |
| Kil et al. | PD-L1 is regulated by interferon gamma and interleukin 6 through STAT1 and STAT3 signaling in cutaneous T-cell lymphoma | |
| Chakraborty et al. | Changes in chemokine receptor expression of regulatory T cells after ex vivo culture | |
| Zaini et al. | The therapeutic strategies of regulatory T cells in malignancies and stem cell transplantations | |
| MX2021006402A (es) | Celulas t-car alogenicas derivadas de placenta y usos de las mismas. | |
| Koolen et al. | Individualized tamoxifen dose escalation | |
| Jia et al. | TIGIT expression positively associates with NK cell function in AML patients | |
| EA202193024A1 (ru) | Анти-cd19-терапия у пациентов с ограниченным числом естественных клеток-киллеров | |
| Tsirigotis et al. | Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine | |
| Wei et al. | Blocking HIF-1α following radiotherapy to prolong and enhance the immune effects of radiotherapy: a hypothesis | |
| Hoffmann et al. | Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells | |
| MX2021010274A (es) | Celulas, composiciones y metodos para mejorar la funcion inmune. | |
| Sutherland | Understanding the Fluctuations in Immune Cell Populations | |
| Fioranelli et al. | Theoretical-Scientific Foundations about the Use of Low-Dose in Oncology | |
| Shah et al. | OAB-017: Attenuation of T cell cytotoxicity mediated by CD200 expression on multiple myeloma cells | |
| RU2013149018A (ru) | Способ оценки тяжести общего состояния больного с острым деструктивным панкреатитом и прогнозирования исхода заболевания |